

Sarah E Seton-Rogers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4167008/publications.pdf>

Version: 2024-02-01

117
papers

919
citations

840585

11
h-index

580701

25
g-index

179
all docs

179
docs citations

179
times ranked

2068
citing authors

#	ARTICLE	IF	CITATIONS
1	One of these things is not like the others. Nature Reviews Cancer, 2016, 16, 5-5.	12.8	3
2	Tracking early tumour cells. Nature Reviews Cancer, 2016, 16, 69-69.	12.8	0
3	Untangling EMT's functions. Nature Reviews Cancer, 2016, 16, 1-1.	12.8	57
4	Order matters. Nature Reviews Genetics, 2015, 16, 193-193.	7.7	0
5	Stressed to bits. Nature Reviews Cancer, 2015, 15, 320-320.	12.8	3
6	An influential delivery. Nature Reviews Cancer, 2015, 15, 386-386.	12.8	0
7	Stress management by the FA pathway. Nature Reviews Cancer, 2015, 15, 699-699.	12.8	0
8	Exploring origins and evolution. Nature Reviews Cancer, 2015, 15, 68-69.	12.8	0
9	Feeding the beast. Nature Reviews Cancer, 2015, 15, 134-134.	12.8	1
10	Mutant relationships. Nature Reviews Cancer, 2015, 15, 135-135.	12.8	1
11	Changing shape. Nature Reviews Cancer, 2015, 15, 71-71.	12.8	1
12	Order matters. Nature Reviews Cancer, 2015, 15, 196-197.	12.8	3
13	APC restores order. Nature Reviews Cancer, 2015, 15, 454-455.	12.8	9
14	MYC maintains high-fidelity splicing. Nature Reviews Cancer, 2015, 15, 385-385.	12.8	3
15	Untangling the role of progesterone receptors. Nature Reviews Cancer, 2015, 15, 456-456.	12.8	4
16	Primed for a response. Nature Reviews Drug Discovery, 2015, 14, 312-312.	21.5	1
17	A circuitous way to target p53. Nature Reviews Cancer, 2015, 15, 318-319.	12.8	8
18	Building bridges. Nature Reviews Cancer, 2015, 15, 199-199.	12.8	1

#	ARTICLE	IF	CITATIONS
19	Primed for a response. Nature Reviews Cancer, 2015, 15, 258-259.	12.8	9
20	A matter of timing. Nature Reviews Cancer, 2015, 15, 256-257.	12.8	3
21	An exhausting metabolic competition. Nature Reviews Cancer, 2015, 15, 573-573.	12.8	3
22	Chromatin reorganization on a 'mega' scale. Nature Reviews Cancer, 2015, 15, 513-513.	12.8	0
23	Model refinement. Nature Reviews Cancer, 2015, 15, 511-511.	12.8	3
24	Place your BETs. Nature Reviews Cancer, 2015, 15, 638-638.	12.8	5
25	Chromatin reorganization on a 'mega' scale. Nature Reviews Genetics, 2015, 16, 499-499.	7.7	2
26	Super-enhanced. Nature Reviews Cancer, 2015, 15, 4-5.	12.8	4
27	Change in schedule. Nature Reviews Cancer, 2014, 14, 153-153.	12.8	1
28	Two might not be better. Nature Reviews Cancer, 2014, 14, 646-646.	12.8	0
29	A clearer pathway view. Nature Reviews Cancer, 2014, 14, 156-157.	12.8	4
30	Carving out a niche. Nature Reviews Cancer, 2014, 14, 516-516.	12.8	0
31	Hippo promotes microRNA processing. Nature Reviews Cancer, 2014, 14, 217-217.	12.8	5
32	A pre-leukaemic reservoir. Nature Reviews Cancer, 2014, 14, 212-212.	12.8	2
33	A clearer pathway view. Nature Reviews Drug Discovery, 2014, 13, 177-177.	21.5	2
34	A cooperative tumour cell community. Nature Reviews Cancer, 2014, 14, 294-294.	12.8	4
35	Competition can be a good thing. Nature Reviews Cancer, 2014, 14, 381-381.	12.8	1
36	Endothelial cells create a niche. Nature Reviews Cancer, 2014, 14, 298-298.	12.8	7

#	ARTICLE	IF	CITATIONS
37	Delving deeper into resistance. Nature Reviews Cancer, 2014, 14, 7-7.	12.8	157
38	Direct hit on mutant RAS. Nature Reviews Cancer, 2014, 14, 8-9.	12.8	7
39	Uncovering new functions of PI3K mutations. Nature Reviews Cancer, 2014, 14, 766-767.	12.8	2
40	All eyes on YAP1. Nature Reviews Cancer, 2014, 14, 515-515.	12.8	11
41	Working in groups. Nature Reviews Cancer, 2014, 14, 645-645.	12.8	0
42	Source influences function. Nature Reviews Cancer, 2014, 14, 705-705.	12.8	2
43	Elongation is essential. Nature Reviews Cancer, 2014, 14, 765-765.	12.8	3
44	Gender differences. Nature Reviews Cancer, 2014, 14, 579-579.	12.8	18
45	Notch blocks bladder tumorigenesis. Nature Reviews Cancer, 2014, 14, 649-649.	12.8	1
46	Fine-tuning metabolism. Nature Reviews Cancer, 2014, 14, 705-705.	12.8	0
47	A better mimic. Nature Reviews Cancer, 2014, 14, 75-75.	12.8	2
48	Cancer stem cell knockout. Nature Reviews Cancer, 2014, 14, 452-453.	12.8	8
49	BETting on epigenetic therapy. Nature Reviews Cancer, 2014, 14, 385-385.	12.8	6
50	Easily moulded. Nature Reviews Cancer, 2013, 13, 519-519.	12.8	5
51	A powerful model. Nature Reviews Cancer, 2013, 13, 8-9.	12.8	1
52	Merlin and ezrin get organized. Nature Reviews Cancer, 2013, 13, 76-76.	12.8	2
53	Means of resistance. Nature Reviews Cancer, 2013, 13, 607-607.	12.8	10
54	Tumours have a lot of nerve. Nature Reviews Cancer, 2013, 13, 608-609.	12.8	3

#	ARTICLE	IF	CITATIONS
55	Teaching old macrophages new tricks. Nature Reviews Cancer, 2013, 13, 753-753.	12.8	10
56	Destroying leukaemia stem cell habitats. Nature Reviews Cancer, 2013, 13, 821-821.	12.8	4
57	No cohesion for cohesin's role. Nature Reviews Cancer, 2013, 13, 825-825.	12.8	0
58	Seeing the big picture. Nature Reviews Cancer, 2013, 13, 683-683.	12.8	1
59	ALL-important mutations. Nature Reviews Cancer, 2013, 13, 151-151.	12.8	1
60	Double trouble. Nature Reviews Cancer, 2013, 13, 6-7.	12.8	1
61	An accommodating host. Nature Reviews Cancer, 2013, 13, 145-145.	12.8	2
62	Fuelling the debate. Nature Reviews Cancer, 2013, 13, 223-223.	12.8	1
63	The cancer X factor. Nature Reviews Cancer, 2013, 13, 224-225.	12.8	19
64	Methylation reboot. Nature Reviews Cancer, 2013, 13, 292-292.	12.8	1
65	At the starting line. Nature Reviews Cancer, 2013, 13, 296-297.	12.8	1
66	Improved detection. Nature Reviews Cancer, 2013, 13, 150-151.	12.8	0
67	Two steps ahead. Nature Reviews Cancer, 2013, 13, 383-383.	12.8	2
68	Metabolic block. Nature Reviews Cancer, 2013, 13, 440-441.	12.8	0
69	Taking it all in. Nature Reviews Cancer, 2013, 13, 438-438.	12.8	0
70	PTEN surprise. Nature Reviews Cancer, 2013, 13, 520-520.	12.8	5
71	Making connections. Nature Reviews Cancer, 2013, 13, 222-223.	12.8	4
72	Coming in waves. Nature Reviews Cancer, 2013, 13, 379-379.	12.8	4

#	ARTICLE	IF	CITATIONS
73	Lines of communication. Nature Reviews Cancer, 2012, 12, 580-581.	12.8	1
74	Multitasking hyaluronic acid. Nature Reviews Cancer, 2012, 12, 228-228.	12.8	19
75	Dynamic interactions. Nature Reviews Cancer, 2012, 12, 378-379.	12.8	6
76	Domino effect. Nature Reviews Cancer, 2012, 12, 506-506.	12.8	0
77	Layered regulation. Nature Reviews Cancer, 2012, 12, 737-737.	12.8	1
78	Recharging with COCO. Nature Reviews Cancer, 2012, 12, 655-655.	12.8	2
79	The new normal. Nature Reviews Cancer, 2012, 12, 660-661.	12.8	0
80	Tumour cells in reverse. Nature Reviews Cancer, 2012, 12, 794-794.	12.8	1
81	Epigenetic therapy gains momentum. Nature Reviews Cancer, 2012, 12, 799-799.	12.8	3
82	Editing changes the meaning. Nature Reviews Cancer, 2012, 12, 797-797.	12.8	4
83	Transforming fusions induce aneuploidy. Nature Reviews Cancer, 2012, 12, 585-585.	12.8	2
84	Pushing pancreatic cancer to take off. Nature Reviews Cancer, 2012, 12, 739-739.	12.8	10
85	siRNAs jump the hurdle. Nature Reviews Cancer, 2012, 12, 376-377.	12.8	15
86	Pump up the volume. Nature Reviews Cancer, 2012, 12, 583-583.	12.8	0
87	Dendritic cell switch. Nature Reviews Cancer, 2012, 12, 231-231.	12.8	9
88	New connections. Nature Reviews Cancer, 2012, 12, 321-321.	12.8	5
89	Field effect. Nature Reviews Cancer, 2012, 12, 508-509.	12.8	7
90	Combinations that work. Nature Reviews Cancer, 2012, 12, 231-231.	12.8	4

#	ARTICLE	IF	CITATIONS
91	Mutational consequences. Nature Reviews Cancer, 2012, 12, 450-451.	12.8	2
92	Finding a rare variant. Nature Reviews Cancer, 2012, 12, 1-1.	12.8	11
93	Signalling in transit. Nature Reviews Cancer, 2012, 12, 5-5.	12.8	10
94	What's the alternative?. Nature Reviews Cancer, 2012, 12, 80-81.	12.8	1
95	Navigating uncharted territory. Nature Reviews Cancer, 2012, 12, 151-151.	12.8	5
96	Scheduled delivery. Nature Reviews Cancer, 2012, 12, 155-155.	12.8	0
97	Model building. Nature Reviews Cancer, 2011, 11, 387-387.	12.8	1
98	HIF switch. Nature Reviews Cancer, 2011, 11, 391-391.	12.8	14
99	Feed it forward. Nature Reviews Cancer, 2011, 11, 461-461.	12.8	5
100	Location, location, location. Nature Reviews Cancer, 2011, 11, 462-463.	12.8	1
101	Driving force. Nature Reviews Cancer, 2011, 11, 539-539.	12.8	6
102	Putting the brakes on lipid loss. Nature Reviews Cancer, 2011, 11, 536-536.	12.8	0
103	Opposing forces in invasion. Nature Reviews Cancer, 2011, 11, 625-625.	12.8	6
104	Flexible flux. Nature Reviews Cancer, 2011, 11, 621-621.	12.8	2
105	Cytokine cues. Nature Reviews Cancer, 2011, 11, 690-690.	12.8	3
106	Layers of regulation. Nature Reviews Cancer, 2011, 11, 689-689.	12.8	2
107	Fibroblast co-conspirators. Nature Reviews Cancer, 2011, 11, 759-759.	12.8	9
108	Catabolic effects. Nature Reviews Cancer, 2011, 11, 757-757.	12.8	3

#	ARTICLE	IF	CITATIONS
109	Another tool in the BCR-ABL kit?. Nature Reviews Cancer, 2011, 11, 833-833.	12.8	1
110	VEGF promotes stemness. Nature Reviews Cancer, 2011, 11, 831-831.	12.8	16
111	Suppressive EPH-ect. Nature Reviews Cancer, 2011, 11, 829-829.	12.8	0
112	Promoting tolerance. Nature Reviews Immunology, 2010, 10, 292-292.	10.6	0
113	Different roads to inactivation. Nature Reviews Cancer, 2009, 9, 610-611.	12.8	7
114	From the editors. Nature Reviews Cancer, 2006, 6, 573-573.	12.8	1
115	Cooperation of the ErbB2 receptor and transforming growth factor β in induction of migration and invasion in mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1257-1262.	3.3	222
116	ErbB2 and TGF-beta: A Cooperative Role in Mammary Tumor Progression?. Cell Cycle, 2004, 3, 595-598.	1.3	14
117	ErbB2 and TGF-beta: a cooperative role in mammary tumor progression?. Cell Cycle, 2004, 3, 597-600.	1.3	14